Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
Steven PipeDepartment of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, USAAbstract: Hemophilia is a rare genetic bleeding disorder that, if not adequately controlled, is associated with life-threatening bleeding events and serious and costly complications, primarily fr...
Guardado en:
Autor principal: | Steven Pipe |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2be17e8d4f794cf6a04c3bbc9f5ae177 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method
por: Berntorp E, et al.
Publicado: (2014) -
Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
por: Wu R, et al.
Publicado: (2020) -
Treatment of hemophilia B: focus on recombinant factor IX
por: Franchini M, et al.
Publicado: (2013) -
Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program
por: Samuel sarmiento Doncel, et al.
Publicado: (2021) -
The management of hemophilia in elderly patients
por: Massimo Franchini, et al.
Publicado: (2007)